Drawing for ANEMOCYTE

USPTO serial 79188650

ANEMOCYTE

Reviewed by CopyMark Law Group

Reg. 5215720Status 706Renewal
Filing date
Status date
Registration date
Jun 6, 2017
Examiner
SAUNDERS, ANDREA DAWN
Law office
TMO LAW OFFICE 137

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Need help with ANEMOCYTE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*

Plus Government fees of $1,950

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Brian A. Tollefson

Brian A. Tollefson Tollefson IP326 First Street, Suite 202Annapolis, MD 21403United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and veterinary preparations, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for use in human [ and veterinary ] medicine; chemical preparations for pharmaceutical or medical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, products for gene therapy, namely, genetically modified cells, viral vectors, nucleic acids; tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; products for personalized medicine made of autologous cells or proteins or nucleid acids derived from individual genomic sequences; preparations made up of cells for medical or clinical use; preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapyACTIVE—
010[ Surgical apparatus and instruments for medical, dental and veterinary use; medical devices for the introduction of pharmaceutical preparations in the human body, in particular syringes and catheters; medical equipment, namely, centrifuges or other separation devices for the isolation of cell sub-populations from tissues and biopsies; surgical apparatus and instruments for medical and veterinary purpose; electrical medical instruments for use in electroporation of cells and tissues for gene transfer purposes, both in vivo and ex-vivo; electronic medical instruments for use in imaging for diagnostic purposes or for monitoring of vital signs of patients ]ACTIVE—
042Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; Providing medical and scientific research information and data on developments in the medical and veterinary fields; scientific and technological services, namely, scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; consultancy to ensure compliance with quality standards and the design and validation of manufacturing processes in the scientific field and medical technology fieldsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 6, 2026REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Jun 4, 2026INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
May 12, 2026INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
May 12, 2026INPCINVALIDATION PROCESSED—
Mar 26, 2026INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Oct 28, 2025INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Sep 30, 2025INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jul 3, 2025RNWLINTERNATIONAL REGISTRATION RENEWED—
Feb 28, 2025NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Feb 28, 202571AGREGISTERED-SEC.71 ACCEPTED—
Nov 15, 2024INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Oct 25, 2024INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Aug 21, 2024EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Feb 24, 2024PR71POST REGISTRATION ACTION MAILED - SEC.71—
Feb 12, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 5, 2023ES71TEAS SECTION 71 RECEIVED—
Oct 24, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 24, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 24, 2022ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Oct 24, 2022EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Oct 24, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 24, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 24, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jun 6, 2022REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Apr 9, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 22, 2018ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Oct 28, 2017FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 14, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 14, 2017FIMPFINAL DISPOSITION PROCESSED—
Sep 6, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 6, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 21, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 21, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 17, 2017GPNXNOTIFICATION PROCESSED BY IB—
Mar 1, 2017OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 1, 2017OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 1, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 14, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 1, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 1, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Feb 1, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 1, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 1, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 1, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Feb 1, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 1, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 1, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 8, 2017GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jan 8, 2017GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jan 8, 2017CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 22, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 22, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 7, 2016ALIEASSIGNED TO LIE—
Nov 16, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 11, 2016ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 11, 2016REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 29, 2016RFNTREFUSAL PROCESSED BY IB—
Jul 13, 2016RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jul 13, 2016RFRRREFUSAL PROCESSED BY MPU—
Jul 12, 2016RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 12, 2016MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 11, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 8, 2016DOCKASSIGNED TO EXAMINER—
Jul 8, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 7, 2016REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance